Kellie Schneider, MD
Gynecologic Oncology · Charlotte, NCNPI 1710195383
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $6,045 of the $7,300 with a category attached, or 82.8%. 6 manufacturers reported payments, led by AstraZeneca at 59.3% of the total.
Across 21 payments — averaging $347.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$4K
- Pfizer$2K
- Biotissue Holdings Inc.$555
- GSK$186
- Eisai Inc.$37
- Intuitive Surgical$32
Across 3 payments — averaging $8822.70 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$26K
What the payments were for
- Consulting fees$6,04583%
- Food & beverage$1,06915%
- Education$1863%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 9 | $4,330 |
| Pfizer | 2 | $2,160 |
| Biotissue Holdings Inc. | 4 | $555 |
| GSK | 3 | $186 |
| Eisai Inc. | 2 | $37 |
| Intuitive Surgical | 1 | $32 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TIVDAK$2,160
How this compares
$7,300 in reported general payments places this provider in the 75th percentile of 52 gynecologic oncology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Clobetasol Propionate | 12 | $356 |
| Oxycodone Hcl | 51 | $198 |
| Ibuprofen | 42 | $165 |
Paid to pharmacies, not to this prescriber.
Other gynecologic oncology in Charlotte
- Robert NaumannCharlotte$221K
- Erin CraneCharlotte$98K
- Jubilee BrownCharlotte$44K
- John McDonaldCharlotte$11K
- Janelle FauciCharlotte$4K
- David TaitCharlotte$2K
- Malcolm RossCharlotte$1K
- Brittany LeesCharlotte$427
- Lucybeth Nieves ArribaWilmington$251K
- Angeles SecordDurham$121K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.